vs
Esperion Therapeutics, Inc.（ESPR）与SHOE CARNIVAL INC（SCVL）财务数据对比。点击上方公司名可切换其他公司
SHOE CARNIVAL INC的季度营收约是Esperion Therapeutics, Inc.的1.8倍（$297.2M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs -3.2%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 3.0%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
Shoe Carnival Inc是一家美国家庭鞋类零售商，目前在美国中西部、南部、东南部地区以及波多黎各共开设了429家门店。该公司由大卫·拉塞尔于1978年创立，截至2025年，其总部位于南卡罗来纳州福特米尔。
ESPR vs SCVL — 直观对比
营收规模更大
SCVL
是对方的1.8倍
$168.4M
营收增速更快
ESPR
高出146.9%
-3.2%
两年增速更快
ESPR
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $297.2M |
| 净利润 | — | $14.6M |
| 毛利率 | — | 37.6% |
| 营业利润率 | 50.6% | 6.3% |
| 净利率 | — | 4.9% |
| 营收同比 | 143.7% | -3.2% |
| 净利润同比 | — | -23.9% |
| 每股收益（稀释后） | $0.32 | $0.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRSCVL
| Q4 25 | $168.4M | $297.2M | ||
| Q3 25 | $87.3M | $306.4M | ||
| Q2 25 | $82.4M | $277.7M | ||
| Q1 25 | $65.0M | $262.9M | ||
| Q4 24 | $69.1M | $306.9M | ||
| Q3 24 | $51.6M | $332.7M | ||
| Q2 24 | $73.8M | $300.4M | ||
| Q1 24 | $137.7M | $280.2M |
净利润ESPRSCVL
| Q4 25 | — | $14.6M | ||
| Q3 25 | $-31.3M | $19.2M | ||
| Q2 25 | $-12.7M | $9.3M | ||
| Q1 25 | $-40.5M | $14.7M | ||
| Q4 24 | — | $19.2M | ||
| Q3 24 | $-29.5M | $22.6M | ||
| Q2 24 | $-61.9M | $17.3M | ||
| Q1 24 | $61.0M | $15.5M |
毛利率ESPRSCVL
| Q4 25 | — | 37.6% | ||
| Q3 25 | — | 38.8% | ||
| Q2 25 | — | 34.5% | ||
| Q1 25 | — | 34.9% | ||
| Q4 24 | — | 36.0% | ||
| Q3 24 | — | 36.1% | ||
| Q2 24 | — | 35.6% | ||
| Q1 24 | — | 35.6% |
营业利润率ESPRSCVL
| Q4 25 | 50.6% | 6.3% | ||
| Q3 25 | -11.4% | 8.2% | ||
| Q2 25 | 8.6% | 4.3% | ||
| Q1 25 | -34.0% | 5.3% | ||
| Q4 24 | -6.4% | 8.0% | ||
| Q3 24 | -31.0% | 9.0% | ||
| Q2 24 | 3.5% | 7.5% | ||
| Q1 24 | 52.5% | 7.1% |
净利率ESPRSCVL
| Q4 25 | — | 4.9% | ||
| Q3 25 | -35.9% | 6.3% | ||
| Q2 25 | -15.4% | 3.4% | ||
| Q1 25 | -62.2% | 5.6% | ||
| Q4 24 | — | 6.3% | ||
| Q3 24 | -57.2% | 6.8% | ||
| Q2 24 | -83.9% | 5.8% | ||
| Q1 24 | 44.3% | 5.5% |
每股收益（稀释后）ESPRSCVL
| Q4 25 | $0.32 | $0.53 | ||
| Q3 25 | $-0.16 | $0.70 | ||
| Q2 25 | $-0.06 | $0.34 | ||
| Q1 25 | $-0.21 | $0.53 | ||
| Q4 24 | $-0.14 | $0.70 | ||
| Q3 24 | $-0.15 | $0.82 | ||
| Q2 24 | $-0.33 | $0.63 | ||
| Q1 24 | $0.34 | $0.57 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $107.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $683.2M |
| 总资产 | $465.9M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRSCVL
| Q4 25 | $167.9M | $107.7M | ||
| Q3 25 | $92.4M | $91.9M | ||
| Q2 25 | $86.1M | $93.0M | ||
| Q1 25 | $114.6M | $123.1M | ||
| Q4 24 | $144.8M | $91.1M | ||
| Q3 24 | $144.7M | $84.5M | ||
| Q2 24 | $189.3M | $69.5M | ||
| Q1 24 | $226.6M | $111.2M |
股东权益ESPRSCVL
| Q4 25 | $-302.0M | $683.2M | ||
| Q3 25 | $-451.4M | $670.7M | ||
| Q2 25 | $-433.5M | $653.6M | ||
| Q1 25 | $-426.2M | $649.0M | ||
| Q4 24 | $-388.7M | $635.7M | ||
| Q3 24 | $-370.2M | $618.5M | ||
| Q2 24 | $-344.2M | $597.8M | ||
| Q1 24 | $-294.3M | $583.4M |
总资产ESPRSCVL
| Q4 25 | $465.9M | $1.2B | ||
| Q3 25 | $364.0M | $1.2B | ||
| Q2 25 | $347.1M | $1.1B | ||
| Q1 25 | $324.0M | $1.1B | ||
| Q4 24 | $343.8M | $1.1B | ||
| Q3 24 | $314.1M | $1.1B | ||
| Q2 24 | $352.3M | $1.1B | ||
| Q1 24 | $373.1M | $1.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $33.6M |
| 自由现金流经营现金流 - 资本支出 | — | $19.7M |
| 自由现金流率自由现金流/营收 | — | 6.6% |
| 资本支出强度资本支出/营收 | 0.0% | 4.7% |
| 现金转化率经营现金流/净利润 | — | 2.30× |
| 过去12个月自由现金流最近4个季度 | — | $35.1M |
8季度趋势，按日历期对齐
经营现金流ESPRSCVL
| Q4 25 | $45.2M | $33.6M | ||
| Q3 25 | $-4.3M | $13.3M | ||
| Q2 25 | $-31.4M | $-9.6M | ||
| Q1 25 | $-22.6M | $44.5M | ||
| Q4 24 | $-35.0M | $17.3M | ||
| Q3 24 | $-35.3M | $23.7M | ||
| Q2 24 | $-7.2M | $17.1M | ||
| Q1 24 | $53.8M | $53.4M |
自由现金流ESPRSCVL
| Q4 25 | — | $19.7M | ||
| Q3 25 | — | $2.2M | ||
| Q2 25 | — | $-23.0M | ||
| Q1 25 | — | $36.2M | ||
| Q4 24 | — | $8.3M | ||
| Q3 24 | $-35.5M | $18.2M | ||
| Q2 24 | $-7.3M | $6.9M | ||
| Q1 24 | $53.8M | $40.7M |
自由现金流率ESPRSCVL
| Q4 25 | — | 6.6% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | -8.3% | ||
| Q1 25 | — | 13.8% | ||
| Q4 24 | — | 2.7% | ||
| Q3 24 | -68.7% | 5.5% | ||
| Q2 24 | -9.9% | 2.3% | ||
| Q1 24 | 39.0% | 14.5% |
资本支出强度ESPRSCVL
| Q4 25 | 0.0% | 4.7% | ||
| Q3 25 | 0.0% | 3.6% | ||
| Q2 25 | 0.0% | 4.8% | ||
| Q1 25 | 0.0% | 3.2% | ||
| Q4 24 | 0.0% | 3.0% | ||
| Q3 24 | 0.3% | 1.7% | ||
| Q2 24 | 0.1% | 3.4% | ||
| Q1 24 | 0.1% | 4.5% |
现金转化率ESPRSCVL
| Q4 25 | — | 2.30× | ||
| Q3 25 | — | 0.69× | ||
| Q2 25 | — | -1.03× | ||
| Q1 25 | — | 3.04× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | 1.05× | ||
| Q2 24 | — | 0.99× | ||
| Q1 24 | 0.88× | 3.44× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
SCVL
暂无分部数据
